KRYS vs LLY

Krystal Biotech maintains its strong '10x potential' trajectory. Vyjuvek's continued robust commercial performance for DEB provides a solid financial base, validating execution. The proprietary STAR-D platform, particularly the AATD program, shows accelerated progress with pivotal clinical readouts anticipated to significantly expand the Total Addressable Market. The leadership's proven ability to...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...